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It  was  shown in  the preceding companion paper  (1)  that  early progressive 
growth of  an immunogenic fibrosarcoma results in the acquisition by its syngeneic 
host of concomitant immunity to growth of a challenge implant, and of tumor- 
sensitized Ly-l-2  + T  cells that are capable of adoptively immunizing against an 
established tumor in y-irradiated recipients. It was shown, in addition, that after 
the tumor reaches a certain size, concomitant immunity and tumor-sensitized T 
cells are progressively lost, and that this is associated with the generation of Ly- 
1  +2- suppressor T  cells capable, on passive transfer, of inhibiting the expression 
of adoptive immunity against an established tumor in T  cell-deficient (TXB) 1 
recipients.  The  evidence was  interpreted  as  showing  that  progressive  tumor 
growth evokes a  mechanism of T  cell-mediated concomitant immunity that is 
down-regulated by suppressor T cells before it develops sufficiently in magnitude 
to destroy the tumor. This knowledge that progressive tumor growth evokes a 
concomitant immune response that subsequently decays under the influence of 
suppressor T  cells must surely be taken into account in assessing the results of 
the  most  commonly used  test  for tumor  immunogenicity (2-4):  determining 
whether surgical removal of a tumor results in immunity to growth of a subse- 
quent implant of cells of that tumor. It might be expected, in this regard, that 
the immunological consequences of excising an immunogenic tumor would be 
determined by whether excision is performed during the generation of concom- 
itant immunity or after it has decayed under the influence of suppressor T  cells. 
It is apparent from the literature (5) that little is known about the relationship 
between the ability to  demonstrate postexcision antitumor immunity and  the 
state of concomitant immunity of the host at the time of excision. 
This paper will show that excising the meth A fibrosarcoma during the time 
that concomitant immunity is being generated results in the preservation of this 
immunity for a long period of time. In contrast, excising the tumor after T  ceil- 
mediated suppression of concomitant immunity does not result in the reemer- 
gence of immunity. Instead, the host remains unresponsive to the meth A tumor 
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and retains a population of suppressor T  cells  capable of passively transferring 
suppression for at least 31  d. 
Materials and Methods 
The materials and methods used in this study are described in the companion paper 
(1), except  regarding tumor excision and the SA-1 sarcoma. Tumor excision was per- 
formed on tumors that were initiated by implanting 106 meth A cells intradermally in the 
midline of the abdomen. At specified days, the tumor-bearing mice were anesthetized 
with Nembutol  (Abbot Laboratories,  North Chicago, IL) and the tumors were removed 
together with 3 mm of the surrounding skin and abdominal wall with scissors. The incision 
was closed with surgical clips and the mice observed for the reemergence of a tumor at 
the site of excision or the development of lymph node metastases. Of mice observed over 
a period of 60 d, only 5% developed lymph node enlargement, and this occurred within 
4 wk. This is in keeping with the fact that the meth A fibrosarcoma is poorly metastatic. 
SA-1 sarcoma cells, syngeneic in A/J mice, were stored over liquid nitrogen. For each 
experiment a vial was thawed, cells washed in phosphate-buffered  saline (PBS), and 106 
of them used to initiate ascites tumors in syngeneic mice. The tumor cells were harvested 
4 d later in heparinized  PBS, washed, and resuspended  appropriately  in PBS. Footpad 
tumors were initiated by injection of 10  n SA-1 cells in the right hind footpad. 
Results 
Postexcision Immunity  Depends on Possession of Concomitant Immunity  at  Time of 
Excision.  By showing that the  removal of chemically induced,  transplantable 
tumors can result in specific immunity of the host to growth of a  subsequent 
implant of tumor cells,  Foley demonstrated in  1953  (6) that syngeneic tumors 
can possess  transplantable rejection antigens.  It  seems  to have been  assumed 
from the time of this demonstration that it is the surgical removal of the tumor 
that causes the emergence of immunity. However, in view of the knowledge that 
the growth of immunogenic tumors can result in the generation of concomitant 
immunity to growth of a tumor cell implant (1,  7), it is possible that there is no 
need to surgically remove these tumors to demonstrate their immunogenicity. It 
is possible, instead, that by preventing death of the host, removal of the tumor 
simply serves to allow an already acquired mechanism of immunity to persist. In 
keeping with this possibility, one might expect that immunity to the growth of a 
challenge implant would not result whether excision is performed before con- 
comitant immunity is generated or after it decays under the influence of sup- 
pressor T  cells.  To investigate these possibilities, mice whose 3,  6,  9,  or  16  d 
meth A tumors had been excised were tested up to 4 wk after excision for their 
ability to express immunity to growth of a  106 challenge implant given in a hind 
footpad. It can  be  seen in  Fig.  1  that only the excision of a  6  or  9  d  tumor 
resulted in a significant level of long-lived immunity to the growth of  the standard 
challenge implant, and that this immunity existed at the time the tumors were 
excised. In contrast, excision of a  3-d tumor resulted in a low level of immunity 
that was very short-lived, and excision of a  16-d tumor resulted in practically no 
immunity to a  challenge implant given up to 28 d later. Thus, on the basis of 
the results in the preceding companion paper (1), we suggest, on the one hand, 
that excising a  3-d tumor failed to result in postexcision immunity because the 
3-d tumor was not large enough to have caused the generation of a significant 
level of concomitant immunity. On the other hand, the  16°d  tumor was more 1314  POSTEXCISION  ANTITUMOR  IMMUNITY  AND  IMMUNOSUPPRESSION 
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FIGURE  1.  The immunological consequence of surgical removal of a 3, 6, 9, or 16 d meth A 
tumor. Removal of a 6 or 9 d tumor left the host with immunity to growth of an antra-footpad 
implant of l0  s tumor cells.  In contrast, excision of a 3-d tumor left the host with partial and 
short-lived immunity to growth of the same sized implant, and excision of a  16-d tumor left 
the host with practically no immunity at all. Means of five mice per group. 
than large enough at the time of excision to have caused the generation of T 
cell-mediated suppression of concomitant immunity. 
Failure  of Immunity  to Emerge After Excising a  16-d  Tumor Is Associated  with an 
Inability  to  Regenerate  Concomitant  Immunity  to  a  Second  Tumor.  The  foregoing 
results show that excising a  tumor that is large enough to have induced a  state 
of  T  cell-mediated  immunosuppression  fails  to  result  in  the  emergence  of 
postexcision immunity to an implant of tumor cells. This could mean that excision 
of the tumor either allowed the host to return to a normal state of immunological 
responsiveness  to  the  tumor  or  caused  the  state  of T  cell-mediated immuno- 
suppression  that existed at  the time of tumor excision to persist.  If the latter 
possibility is correct, then it would follow that a host that has had its 16-d tumor BURSUKER  AND  NORTH  1315 
removed should be unable to generate concomitant immunity to growth of a 
second tumor. That this proved to be the case is shown in Fig. 2 where it can be 
seen that whereas mice bearing a  meth A  tumor for the first time generated 
concomitant immunity to  a  tumor  implant by day  9  of tumor growth,  mice 
bearing a second 9-d meth A tumor that was initiated 1 wk after the excision of 
a  16-d primary tumor, failed to express concomitant immunity to the same sized 
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FIGURE 2.  Evidence that a  host whose  16-d meth A  tumor is surgically removed does not 
regenerate to a  normal state of immunological responsiveness to this tumor, as indicated by 
the absence of a capacity to regenerate concomitant immunity to a second tumor. (Left) Growth 
of an intra-footpad challenge of 10  6 tumor cells in control mice (without a  tumor) and mice 
bearing a  9-d  primary  tumor.  (Righ  0  Behavior of the  same-sized  intra-footpad  challenge 
implant in mice whose  16-day tumors were removed  16 d  earlier (without tumor) and mice 
whose  16-d  tumors  were  removed  16  d  earlier  and  were  bearing  a  9-d  tumor  initiated 
intradermally in the belly region 7 d after excision of the first tumor. Concomitant immunity 
was not generated against the second tumor. Means of five mice per group. 
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FIGURE  3.  Evidence that a host whose 16-d meth A tumor is surgically removed 2 wk earlier 
retains the ability to reject an allogeneic tumor. (Left) Growth of an intra-footpad challenge of 
6  6  10  allogeneic SA-] or  10  meth A cells in normal control mice. (Right) Growth of the same- 
sized implants of SA-1 cells or meth A cells in postexcision mice. 1316  POSTEXCISION  ANTITUMOR  IMMUNITY  AND  IMMUNOSUPPRESSION 
implant.  This  result  indicates,  therefore, that  the host remained immunosup- 
pressed after the removal of its  16-d tumor. However, this immunosuppression 
does not  represent a  state  of generalized nonspecific immunosuppression,  as 
evidenced by  the  retained ability  of the  animals  to  reject an  implant  of an 
allogeneic tumor, the SA-1  sarcoma. It can be seen in Fig. 3 that the SA-1 grew 
to the same size in control and postexcision mice, before being rapidly rejected 
with the same efficiency by both. 
Postexcision Immunosuppression  Is Associated with  the Protracted  Possession of Ly- 
1+2 -  T Cells Capable of Passively Transferring  Suppression to TXB Recipients.  If, as 
the preceding results  suggest,  excising a  tumor that  is  large enough to  have 
induced immunosuppression does not result in the return of normal immunolog- 
ical reactivity, then it is likely that the host retains the suppressor T  cells that 
were generated before excision was performed. This was investigated by excising 
16-d tumors from a number of mice and dividing them into groups according to 
whether they were used as donors of suppressor T  cells just before excision or 
1, 7, 21, or 31 d later. Suppression was measured in terms of the capacity of one 
organ equivalent (1.5  x  l0 s) of spleen cells to inhibit, on passive transfer, the 
capacity of one organ equivalent of immune spleen cells infused 3 h  earlier to 
cause the regression of an established tumor in a TXB test recipient (8, 0). 
It can be seen in Fig. 4 that the ability of spleen cells from donors with a  16-d 
tumor to  inhibit the expression of adoptive immunity did not disappear after 
excision of the  tumor.  Instead,  appreciable  suppression  of the  expression  of 
adoptive immunity could be demonstrated with spleen cells harvested up to 31 
d  after  tumor  excision.  It  is  apparent,  however, that  suppression  slowly and 
progressively decayed over this 31 d period. 
The cells with suppressor function present in the spleen 2 wk after the excision 
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FIGURE 4.  Mice that had their  16-d tumors removed continued to possess splenic T  cells 
capable, on passive transfer, of suppressing the expression of adoptive immunity. When TXB 
recipients bearing 3-d tumors were infused with  1.5  x  108 spleen cells from donors preim- 
munized 3 wk earlier with l0  s meth A cells admixed with 100 ,g ofC. parvum, the tumors in 
all of these recipients underwent complete regression (lmm. control). Tumor regression failed 
to occur, however, if the recipients were also infused 3 h later with one organ equivalent (~ 1.5 
x  10  s) of spleen cells from donors whose 16-d tumors were removed from 1 d earlier (Imm. 
+  T1  PE.S) to 31 d earlier (Imm. +  T31 PE.S). Means of five mice per group. BURSUKER  AND  NORTH  1317 
240  e--e  Tumor control 
•  •  Imm. control 
u--u  tram.+  PE. S.  / 
"--"  Imm.+  ,,  ,,  (C')  •~ 
200  m--I:  Imm.+  ,  ,  (,,-Thy -I- C')~ 
|  /  ..0  ./.  ,¢ 
°  /  ,//  O  120 
o,.,  so  I 
40- 
O  /  I  I  I  I  ~''''' 
0  4  8  12  16  20  24 
DAYS 
FIGURE 5.  The suppressor ceils in the spleen of mice whose  16-d tumors were removed 2 
wk earlier were T  cells. Infusion of immune cells alone (Imm. control) into TXB recipients 
bearing a  3-d tumor (arrow) resulted in complete tumor regression.  However, infusion 3 h 
after immune cells of 1.5 x  10  8 spleen cells from donors whose 16-d tumors were removed 14 
d  earlier (Imm.  +  PE.S  [postexcision  suppressor  cells])  prevented  tumor  regression  from 
occuring. This suppressor activity was eliminated by treating the spleen cells with anti-Thy- 
1.2 antibody and C' but not with C' alone. Means of five mice per group. 
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FIGURE  6.  Evidence that postexcision suppressor T  cells are Ly-l+2  -. An established tumor 
in TXB recipients underwent  complete regression after the infusion of immune cells alone 
(Imm. control) but not after infusion of immune T  cells plus suppressor T  cells (Imm. + PE,S) 
from  suppressor  donors  whose  16-d  tumors  were  removed 2  wk  earlier.  The  suppressor 
function of the spleen cells was eliminated by treatment with anti-Ly-1 antibody and C', but 
not by treatment with anti-Ly-2 antibody and C'. Means of five mice per group. 1318  POSTEXCISION  ANTITUMOR  IMMUNITY  AND  IMMUNOSUPPRESSION 
ofa 16-d tumor were T  cells, as evidenced by the finding (Fig. 5) that they were 
functionally eliminated by treatment with anti-Thy-l.2 antibody and  comple- 
ment. Moreover, like the T cells responsible for active suppression of concomitant 
immunity in the preceding paper (1),  the suppressor T  cells that were retained 
after the excision of a  16-d tumor were of the Ly-l÷2  -  phenotype, in that they 
were eliminated by treatment with anti-Ly-1 antibody and complement but not 
by anti-Ly-2 antibody and complement (Fig. 6). 
Discussion 
This  study  shows  that  predicting  the  immunological  consequences of the 
surgical removal of an immunogenic tumor requires a knowledge of the kinetics 
of the  host's  concomitant immune response  to  the  tumor.  According to  the 
results in the preceding companion paper (1),  growth of the nonmetastasizing 
meth A fibrosarcoma in its syngeneic host results, between days 6 and 9, in the 
generation of concomitant immunity to the growth of a  tumor implant and in 
the  parallel  generation  of  Ly-l-2  +  T  cells  capable  of passively  transferring 
immunity against an established tumor to ~-irradiated recipients.  In addition, 
the companion paper showed that both the decay of concomitant immunity and 
the loss of Ly- 1-2+-sensitized T  cells that occurs after day 9 of tumor growth is 
associated with the progressive generation of Ly-l+2  - suppressor T  cells able to 
suppress the expression of adoptive immunity against an established tumor in 
TXB recipients. It perhaps is not surprising,  therefore, that the present paper 
shows that  in  order for tumor excision to  result in  immunity to  growth of a 
subsequent implant of tumor cells, excision must be performed while concomitant 
immunity is being generated and expressed. Therefore, the excision of a tumor 
does  not  cause  immunity to  be  generated,  but  serves  to  preserve a  state  of 
immunity that already exists and which otherwise would undergo rapid T  cell- 
mediated suppression if the tumor were allowed to increase in size.  The results 
suggest that earlier categorization of tumors as immunogenic, on the basis of 
postexcision immunity to growth of a challenge implant (2-4,  10-13), may not 
have  required excision of the  tumors at  all.  This  study also  shows  that  it  is 
possible,  by excising a  tumor when it  is  too small to evoke the generation of 
concomitant immunity, or when it is  large enough to  induce T  cell-mediated 
suppression of immunity, to falsely conclude that a  tumor is nonimmunogenic. 
This might be the reason why a given tumor can be immunogenic in the hands 
of some investigators but nonimmunogenic in the hands of others. 
However, this study does not provide information about the mechanism of 
postexcision  immunity.  It  remains  possible,  therefore,  that  it  is  functionally 
different from the concomitant immunity that exists at the time of excision. It is 
likely, for example, that  if concomitant immunity represents a  state of active 
immunity mediated by cytolytic effector T  cells, as suggested in the companion 
paper (1), then excising a 9-d tumor might result in the rapid decay of this active 
immunity and in the subsequent emergence of  a long-lived state of immunological 
memory. Indeed, recent studies in this laboratory (Bursuker and North, manu- 
script  in  preparation)  have  revealed that  long-lived, postexcision immunity is 
based on the possession of a T  cell population physiologically different from the 
effector T  cells that mediate the concomitant immunity that exists at the time BURSUKER  AND  NORTH  1319 
excision is performed. Needless to say, a state of immunological memory never 
develops if a tumor is allowed to grow progressively, because the host dies. But 
even if the host were to survive for a long period of time, immunological memory 
still  would fail to develop, because an increasing load of tumor antigen would 
result  in  the  generation  of a  state  of T  cell-mediated  immunosuppression. 
Moreover, according to the results of this study, the state of immunosuppression 
persists even after the tumor that caused its generation is excised. Consequently, 
a host that has had a  16-d meth A tumor removed remains unable to regenerate 
concomitant immunity to a second tumor and continues to possess, for at least a 
31-d period, Ly-1 +2- splenic T  cells capable, on passive transfer, of suppressing 
the expression of adoptive immunity against an established tumor in TXB test 
recipients. Therefore, the host continues to possess suppressor T  cells with the 
same Ly phenotype as the suppressor T cells that actively suppressed concomitant 
immunity (1).  The level of suppression, however, progressively decays over this 
31-d period. Moreover, a  more recent study (Bursuker and North, manuscript 
in  preparation)  has  revealed  that  T  cells able  to  suppress  the  expression  of 
adoptive  immunity in  tumor-bearing TXB  recipients  disappeared  by  day  60 
postexcision,  but  that  the  mice  surprisingly  continued  to  exhibit  diminished 
capacity to generate concomitant immunity. This study has shown, in addition, 
that the diminished capacity for generating concomitant immunity is associated 
with  an  ability  to  regenerate  suppressor  T  cells  in  an  accelerated  manner, 
indicating the possession of "memory suppression" as recently shown by results 
from another laboratory (14). The persistence of this long-lived state of T  cell- 
mediated immunosuppression in the apparent absence of antigen, likens tumor- 
induced immunosuppression to immunological tolerance of the type that can be 
generated against histocompatibility antigens (15,  16).  For it is now well estab- 
lished that tolerance of histocompatibility antigens is actively sustained by sup- 
pressor T  cells that enable it to be passively transferred to appropriate recipients 
(17). 
It should be pointed out finally that because surgical removal of an immuno- 
genic  tumor  does  not  result  in  the abridgement of tumor-induced immuno- 
suppression, it is unlikely that immunotherapy of systemic disease will be more 
successful if performed after the removal of the primary tumor burden.  For 
immunotherapy to be successful under these conditions, agents would need to 
be administered that would preferentially eliminate suppressor T  cells. 
Summary 
This study shows that surgical removal of the meth A  fibrosarcoma from its 
semisyngeneic host fails to result in postexcision immunity to growth of a tumor 
implant  unless  the  host  already  has  acquired  a  mechanism  of concomitant 
immunity to growth of an implant.  Therefore, tumor excision does not cause 
immunity to be generated but preserves a mechanism of concomitant immunity 
that already exists and which otherwise would eventually undergo down-regula- 
tion under the influence of suppressor T  cells. Removal of the tumor after it has 
grown large enough to cause the T  cell-mediated suppression of concomitant 
immunity does not result  in  the reemergence of immunity. Instead,  the host 
remains unable to generate concomitant immunity to a second tumor for a long 1320  POSTEXCISION  ANTITUMOR  IMMUNITY  AND  IMMUNOSUPPRESSION 
period of time and retains, for at least 31  d, suppressor T  cells able to passively 
transfer suppression  to appropriate  recipients.  Like the suppressor  T  cells re- 
sponsible for active suppression of concomitant immunity, the suppressor T  cells 
responsible for "memory" suppression are of the Ly-1 +2- phenotype. The results 
indicate  that  progressive  tumor  growth  results  in  a  state  of  immunological 
tolerance  of  tumor-specific,  transplantation  antigens  that  can  persist  in  the 
apparent absence of tumor antigens. 
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